Search Within

Robert Motzer

Formats
  1. Journal Article (609)
  2. Meeting Abstract (578)
  3. Book Section (20)
  4. Review (13)
  5. Conference Paper (6)
  6. Correspondence (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (3)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1247)
  2. Genitourinary Oncology Service (1247)
  3. Solid Tumor Oncology Division (1247)
  4. Surgery (290)
  5. Urology (281)
  6. Survivorship Research (253)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (30)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Elsevier Science, Inc. (111)
  3. Oxford University Press (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (86)
  6. American Association for Cancer Research (58)

More Publishers

Results (1247)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus cabozantinib (N+C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Meeting Abstract

    Pook, D.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; more...
    Asia-Pacific Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of avelumab + axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101
    Meeting Abstract

    Haanen, J.; Larkin, J.; Choueiri, T.; Albiges, L.; Rini, B.; Atkins, M.; Schmidinger, M.; Penkov, K.; Thomaidou, D.; Wang, J.; more...
    Asia-Pacific Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Meeting Abstract

    Porta, C. G.; Burotto, M.; Suarez Rodriguez, C.; Bourlon, M. T.; Hsieh, J.; Shah, A. Y.; Hamzaj, A.; Bedke, J.; Pook, D.; Kessler, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Porta, C. G.; Motzer, R.; Ejzykowicz, F.; Blum, S. I.; Hamilton, M.; May, J. R.; Huo, S.; Kral, P.; Ivanescu, C.; Choueiri, T. K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
    Meeting Abstract

    Choueiri, T. K.; Eto, M.; Kopyltsov, E.; Rha, S. Y.; Porta, C. G.; Motzer, R.; Grünwald, V.; Hutson, T. E.; Méndez-Vidal, M. J.; Hong, S. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Tannir, N. M.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C. G.; George, S.; Powles, T. B.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A qualitative framework of non-selection factors for cytoreductive nephrectomy
    Journal Article

    Silagy, A. W.; Attalla, K.; Dinatale, R. G.; Weiss, K. L.; Weng, S.; Mano, R.; Iosepovici, S.; Marcon, J.; Reznik, E.; Kotecha, R. R.; more...
    World Journal of Urology (2021)

    Fulltext@MSK | Save
  • Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma
    Journal Article

    Silagy, A. W.; Kotecha, R. R.; Weng, S.; Holmes, A.; Singla, N.; Mano, R.; Attalla, K.; Weiss, K. L.; DiNatale, R. G.; Patil, S.; more...
    Cancer (2021)

    Fulltext@MSK | Save
  • Prevalence and landscape of actionable genomic alterations in renal cell carcinoma
    Journal Article

    Attalla, K.; DiNatale, R. G.; Rappold, P. M.; Fong, C. J.; Sanchez-Vega, F.; Silagy, A. W.; Weng, S.; Coleman, J.; Lee, C. H.; Carlo, M. I.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • High response rate and durability driven by HLA genetic diversity in patients with kidney cancer treated with lenvatinib and pembrolizumab
    Journal Article

    Lee, C. H.; DiNatale, R. G.; Chowell, D.; Krishna, C.; Makarov, V.; Valero, C.; Vuong, L.; Lee, M.; Weiss, K.; Hoen, D.; more...
    Molecular Cancer Research (2021)

    Fulltext@MSK | Save